Baidu
map

Int J Cancer:长期职业性接触木屑会增加鼻腺癌的风险(病例对照研究)

2017-08-29 MedSci MedSci原创

世界卫生组织国际癌症研究中心(IARC)公布的致癌物列表中,木屑被列为了一类致癌物。与木屑有关的常见癌症包括鼻腔癌和鼻窦癌,肺癌,胃肠癌,以及涉及喉咙和呼吸道系统的癌症。除了癌症以外,木屑还会导致皮炎,过敏性反应,呼吸困难,瘙痒,皮肤刺激和视力问题。鼻癌或者鼻腔癌,是指鼻部或者鼻腔的恶性肿瘤,最常见的有鼻腔恶性淋巴瘤,鼻咽癌和其它肿瘤,其发病原因主要与遗传,病毒感染,及环境因素等有关。研究人员对芬

世界卫生组织国际癌症研究中心(IARC)公布的致癌物列表中,木屑被列为了一类致癌物。与木屑有关的常见癌症包括鼻腔癌和鼻窦癌,肺癌,胃肠癌,以及涉及喉咙和呼吸道系统的癌症。除了癌症以外,木屑还会导致皮炎,过敏性反应,呼吸困难,瘙痒,皮肤刺激和视力问题。

鼻癌或者鼻腔癌,是指鼻部或者鼻腔的恶性肿瘤,最常见的有鼻腔恶性淋巴瘤,鼻咽癌和其它肿瘤,其发病原因主要与遗传,病毒感染,及环境因素等有关。

研究人员对芬兰、瑞典、挪威和冰岛,四个北欧国家的从事木材加工的不同行业的人群进行了研究。本研究的目的是提供更有力的证据来帮助临床医生了解混合木屑的终生职业暴露(软木材占主导地位)在鼻腔癌病因学中的作用。

这是一个以人群为基础的病例-对照研究,包括在1961-2005年间在四个国家诊断的所有鼻腺癌(393例)、其他类型的鼻腔癌(2446)和鼻咽癌(1747)男性。研究人员对在确诊病例(索引日期)时依然存活的癌症患者,根据出生年份和国家按1:5随机匹配男性对照组。在索引日期之前的木屑和甲醛的累积曝光(CE)根据一个基于人口普查的工种-工作暴露来量化。研究人员还使用条件logistic回归法估算了木屑CE的危险比(HRS),还计算了调整后木屑/甲醛的比值和95%置信区间。

研究发现,接触木屑与鼻腺癌风险增加相关。木尘累积暴露最高的分级(≥28.82mg/[立方米-年])的HR为16.5(95% CI 5.05-54.1)。无论是非鼻腺癌,还是鼻咽癌都不与接触木屑相关。

研究人员认为,以软木材为主的混合木屑的终生CE与鼻腺癌风险的增高强烈相关,而与其他类型鼻腔癌或鼻咽癌无关。

原始出处:


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1984129, encodeId=9d351984129a4, content=<a href='/topic/show?id=77dee0776b6' target=_blank style='color:#2F92EE;'>#病例对照研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70776, encryptionId=77dee0776b6, topicName=病例对照研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Fri Apr 13 12:58:00 CST 2018, time=2018-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756159, encodeId=dd731e56159fa, content=<a href='/topic/show?id=cc81e0775ab' target=_blank style='color:#2F92EE;'>#病例对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70775, encryptionId=cc81e0775ab, topicName=病例对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=064637073830, createdName=xugc, createdTime=Wed Nov 01 19:58:00 CST 2017, time=2017-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775336, encodeId=b7da1e7533656, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Tue Jul 10 09:58:00 CST 2018, time=2018-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=238565, encodeId=b7d3238565b3, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Wed Aug 30 07:50:40 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=238454, encodeId=b61223845494, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/29/b3bfbf505d0fa409645d107d6f199df4.jpg, createdBy=e1552135942, createdName=上帝的天使, createdTime=Tue Aug 29 23:11:30 CST 2017, time=2017-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=238453, encodeId=706623845385, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K4PNicOvbHfgIficrsEKztlD5yv1UnCFhnFmFU9yv1RHLflMRibWrppbsiccfMB8tT9HCkAr3zL2zVml/0, createdBy=89da1604922, createdName=䖝二, createdTime=Tue Aug 29 23:08:39 CST 2017, time=2017-08-29, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1984129, encodeId=9d351984129a4, content=<a href='/topic/show?id=77dee0776b6' target=_blank style='color:#2F92EE;'>#病例对照研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70776, encryptionId=77dee0776b6, topicName=病例对照研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Fri Apr 13 12:58:00 CST 2018, time=2018-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756159, encodeId=dd731e56159fa, content=<a href='/topic/show?id=cc81e0775ab' target=_blank style='color:#2F92EE;'>#病例对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70775, encryptionId=cc81e0775ab, topicName=病例对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=064637073830, createdName=xugc, createdTime=Wed Nov 01 19:58:00 CST 2017, time=2017-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775336, encodeId=b7da1e7533656, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Tue Jul 10 09:58:00 CST 2018, time=2018-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=238565, encodeId=b7d3238565b3, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Wed Aug 30 07:50:40 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=238454, encodeId=b61223845494, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/29/b3bfbf505d0fa409645d107d6f199df4.jpg, createdBy=e1552135942, createdName=上帝的天使, createdTime=Tue Aug 29 23:11:30 CST 2017, time=2017-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=238453, encodeId=706623845385, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K4PNicOvbHfgIficrsEKztlD5yv1UnCFhnFmFU9yv1RHLflMRibWrppbsiccfMB8tT9HCkAr3zL2zVml/0, createdBy=89da1604922, createdName=䖝二, createdTime=Tue Aug 29 23:08:39 CST 2017, time=2017-08-29, status=1, ipAttribution=)]
    2017-11-01 xugc
  3. [GetPortalCommentsPageByObjectIdResponse(id=1984129, encodeId=9d351984129a4, content=<a href='/topic/show?id=77dee0776b6' target=_blank style='color:#2F92EE;'>#病例对照研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70776, encryptionId=77dee0776b6, topicName=病例对照研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Fri Apr 13 12:58:00 CST 2018, time=2018-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756159, encodeId=dd731e56159fa, content=<a href='/topic/show?id=cc81e0775ab' target=_blank style='color:#2F92EE;'>#病例对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70775, encryptionId=cc81e0775ab, topicName=病例对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=064637073830, createdName=xugc, createdTime=Wed Nov 01 19:58:00 CST 2017, time=2017-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775336, encodeId=b7da1e7533656, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Tue Jul 10 09:58:00 CST 2018, time=2018-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=238565, encodeId=b7d3238565b3, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Wed Aug 30 07:50:40 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=238454, encodeId=b61223845494, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/29/b3bfbf505d0fa409645d107d6f199df4.jpg, createdBy=e1552135942, createdName=上帝的天使, createdTime=Tue Aug 29 23:11:30 CST 2017, time=2017-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=238453, encodeId=706623845385, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K4PNicOvbHfgIficrsEKztlD5yv1UnCFhnFmFU9yv1RHLflMRibWrppbsiccfMB8tT9HCkAr3zL2zVml/0, createdBy=89da1604922, createdName=䖝二, createdTime=Tue Aug 29 23:08:39 CST 2017, time=2017-08-29, status=1, ipAttribution=)]
    2018-07-10 amyloid
  4. [GetPortalCommentsPageByObjectIdResponse(id=1984129, encodeId=9d351984129a4, content=<a href='/topic/show?id=77dee0776b6' target=_blank style='color:#2F92EE;'>#病例对照研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70776, encryptionId=77dee0776b6, topicName=病例对照研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Fri Apr 13 12:58:00 CST 2018, time=2018-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756159, encodeId=dd731e56159fa, content=<a href='/topic/show?id=cc81e0775ab' target=_blank style='color:#2F92EE;'>#病例对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70775, encryptionId=cc81e0775ab, topicName=病例对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=064637073830, createdName=xugc, createdTime=Wed Nov 01 19:58:00 CST 2017, time=2017-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775336, encodeId=b7da1e7533656, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Tue Jul 10 09:58:00 CST 2018, time=2018-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=238565, encodeId=b7d3238565b3, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Wed Aug 30 07:50:40 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=238454, encodeId=b61223845494, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/29/b3bfbf505d0fa409645d107d6f199df4.jpg, createdBy=e1552135942, createdName=上帝的天使, createdTime=Tue Aug 29 23:11:30 CST 2017, time=2017-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=238453, encodeId=706623845385, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K4PNicOvbHfgIficrsEKztlD5yv1UnCFhnFmFU9yv1RHLflMRibWrppbsiccfMB8tT9HCkAr3zL2zVml/0, createdBy=89da1604922, createdName=䖝二, createdTime=Tue Aug 29 23:08:39 CST 2017, time=2017-08-29, status=1, ipAttribution=)]
    2017-08-30 130****4638

    学习了谢谢分享

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1984129, encodeId=9d351984129a4, content=<a href='/topic/show?id=77dee0776b6' target=_blank style='color:#2F92EE;'>#病例对照研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70776, encryptionId=77dee0776b6, topicName=病例对照研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Fri Apr 13 12:58:00 CST 2018, time=2018-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756159, encodeId=dd731e56159fa, content=<a href='/topic/show?id=cc81e0775ab' target=_blank style='color:#2F92EE;'>#病例对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70775, encryptionId=cc81e0775ab, topicName=病例对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=064637073830, createdName=xugc, createdTime=Wed Nov 01 19:58:00 CST 2017, time=2017-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775336, encodeId=b7da1e7533656, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Tue Jul 10 09:58:00 CST 2018, time=2018-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=238565, encodeId=b7d3238565b3, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Wed Aug 30 07:50:40 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=238454, encodeId=b61223845494, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/29/b3bfbf505d0fa409645d107d6f199df4.jpg, createdBy=e1552135942, createdName=上帝的天使, createdTime=Tue Aug 29 23:11:30 CST 2017, time=2017-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=238453, encodeId=706623845385, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K4PNicOvbHfgIficrsEKztlD5yv1UnCFhnFmFU9yv1RHLflMRibWrppbsiccfMB8tT9HCkAr3zL2zVml/0, createdBy=89da1604922, createdName=䖝二, createdTime=Tue Aug 29 23:08:39 CST 2017, time=2017-08-29, status=1, ipAttribution=)]
    2017-08-29 上帝的天使

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1984129, encodeId=9d351984129a4, content=<a href='/topic/show?id=77dee0776b6' target=_blank style='color:#2F92EE;'>#病例对照研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70776, encryptionId=77dee0776b6, topicName=病例对照研究)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Fri Apr 13 12:58:00 CST 2018, time=2018-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756159, encodeId=dd731e56159fa, content=<a href='/topic/show?id=cc81e0775ab' target=_blank style='color:#2F92EE;'>#病例对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70775, encryptionId=cc81e0775ab, topicName=病例对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=064637073830, createdName=xugc, createdTime=Wed Nov 01 19:58:00 CST 2017, time=2017-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1775336, encodeId=b7da1e7533656, content=<a href='/topic/show?id=937d46650bf' target=_blank style='color:#2F92EE;'>#对照#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46650, encryptionId=937d46650bf, topicName=对照)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ae138776909, createdName=amyloid, createdTime=Tue Jul 10 09:58:00 CST 2018, time=2018-07-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=238565, encodeId=b7d3238565b3, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Wed Aug 30 07:50:40 CST 2017, time=2017-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=238454, encodeId=b61223845494, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/29/b3bfbf505d0fa409645d107d6f199df4.jpg, createdBy=e1552135942, createdName=上帝的天使, createdTime=Tue Aug 29 23:11:30 CST 2017, time=2017-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=238453, encodeId=706623845385, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=2, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K4PNicOvbHfgIficrsEKztlD5yv1UnCFhnFmFU9yv1RHLflMRibWrppbsiccfMB8tT9HCkAr3zL2zVml/0, createdBy=89da1604922, createdName=䖝二, createdTime=Tue Aug 29 23:08:39 CST 2017, time=2017-08-29, status=1, ipAttribution=)]
    2017-08-29 䖝二

    学习了

    0

Baidu
map
Baidu
map
Baidu
map